Venture Capital Investors

Vivo Capital

Vivo Capital is a VC firm investing in tech companies.

Venture Investor Overview

Venture Investor
Vivo Capital
Status
Active
Investor Type
Venture Capital
Activity Level
147 transactions
Funds Raised
At least $2.8 billion
Industry Focus
Biopharmaceutical
FinTech
Healthcare IT
Healthcare Services
Medical Devices & Instruments

Contact Information

Contact
Frank Kung
Title
Managing Partner
Mailing Address
192 Lytton Ave. 207
Palo Alto, CA 94301
USA
Phone
(650) 688-0818
Website
www.vivocapital.net
Email Address
Not Recorded

Background Information

Overview
Founded in 1996, Vivo Capital is a healthcare investment firm focused on investing in and building high quality companies in the U.S. and China. Vivo employs a unique multi-pronged strategy of identifying and working with companies with promising development stage and commercial stage therapeutic products in the U.S. and revenue stage companies in China.
Profile
Vivo Capital LinkedIn Company Profile
Social Media
Vivo Capital Company Twitter Account
Company News
Vivo Capital News
Facebook
Vivo Capital on Facebook
YouTube
Vivo Capital on YouTube
Last Transaction
3/20/2024

Transaction History

Our records indicate that Vivo Capital invested in the VC transactions listed below. Dollar amounts are for the entire raise, which may include other investors.

Company
Date
Amount
Clasp Therapeutics
3/20/2024
$150,000,000
COMPASS Pathways
8/18/2023
$285,000,000
ADARx Pharmaceuticals
8/9/2023
$200,000,000
Ossium Health
7/25/2023
$52,000,000
EpiBiologics
7/20/2023
$23,000,000
Delcath Systems
3/28/2023
$85,000,000
EpiBiologics
3/22/2023
$50,000,000
Ronovo Surgical
2/1/2023
$50,000,000
Pulmocide
12/6/2022
$52,000,000
Zenas BioPharma
11/8/2022
$118,000,000
Neocis
10/27/2022
$40,000,000
Klavi
8/13/2022
$15,000,000
Inspirna
7/11/2022
$50,000,000
Tebra
7/7/2022
$72,000,000
Cerebral Therapeutics
6/28/2022
$40,000,000
Ocelot Bio
3/23/2022
$36,000,000
Avistone Pharmaceuticals
12/9/2021
$200,000,000
Attralus
9/9/2021
$116,000,000
InBrace
9/9/2021
$102,000,000
Neurogastrx
8/27/2021
$60,000,000
RayzeBio
6/16/2021
$108,000,000
Scientia Vascular
5/28/2021
$50,000,000
Aerobiotix
5/7/2021
$25,000,000
Sera Prognostics
4/30/2021
$100,000,000
Immune-Onc Therapeutics
4/1/2021
$73,000,000
Fortis Therapeutics
3/30/2021
$40,000,000
Ossium Health
3/22/2021
$63,000,000
Ventyx Biosciences
3/10/2021
$114,000,000
BlossomHill Therapeutics
3/5/2021
$71,000,000
Design Therapeutics
1/28/2021
$125,000,000
Kira Pharmaceuticals
1/8/2021
$53,500,000
Terns Pharmaceuticals
1/6/2021
$87,000,000
Elevation Oncology
11/19/2020
$65,000,000
Neocis
10/9/2020
$72,000,000
Olema Oncology
10/2/2020
$85,000,000
PatientPop
9/1/2020
$50,000,000
Tranquis Therapeutics
7/10/2020
$30,000,000
Bolt Biotherapeutics
7/2/2020
$93,500,000
Tarsus Pharmaceuticals
1/9/2020
$60,000,000
Cerebral Therapeutics
1/9/2020
$35,000,000
Swift Health Systems
10/9/2019
$45,000,000
Revolution Medicines
7/11/2019
$100,000,000
IGM Biosciences
7/9/2019
$102,000,000
Poseida Therapeutics
4/23/2019
$142,000,000
Cerebral Therapeutics
3/11/2019
$7,800,000
MacuLogix
3/5/2019
$38,700,000
Passage Bio
2/19/2019
$115,500,000
Bolt Biotherapeutics
2/6/2019
$54,000,000
Impel NeuroPharma
12/7/2018
$67,500,000
Terns Pharmaceuticals
10/31/2018
$80,000,000
Immune-Onc Therapeutics
9/20/2018
Unknown
Precision BioSciences
6/27/2018
$110,000,000
Cerebral Therapeutics
6/21/2018
$3,000,000
Metacrine
6/8/2018
$65,000,000
Poseida Therapeutics
4/4/2018
$30,500,000
Crinetics Pharmaceuticals
3/15/2018
$63,500,000
Medeor Therapeutics
11/28/2017
$57,000,000
Outpost Medicine
11/16/2017
$20,000,000
Tricida
11/9/2017
$57,500,000
Harmony Biosciences
10/10/2017
$270,000,000
Apellis Pharmaceuticals
8/11/2017
$60,000,000
Homology Medicines
8/2/2017
$83,500,000
Menlo Therapeutics
7/19/2017
$50,000,000
Platelet Biogenesis
6/9/2017
$10,000,000
Aadi Bioscience
5/9/2017
$23,000,000
Impel NeuroPharma
12/6/2016
$36,000,000
Biohaven Pharmaceuticals
11/2/2016
$80,000,000
SentreHEART
9/29/2016
$35,000,000
Fortis Therapeutics
9/28/2016
$18,000,000
Tricida
7/26/2016
$55,000,000
Kala Pharmaceuticals
4/14/2016
$68,000,000
Minerva Surgical
3/31/2016
$15,000,000
Outpost Medicine
3/16/2016
$41,000,000
Crinetics Pharmaceuticals
11/3/2015
$40,000,000
Nexcida Therapeutics
6/30/2015
$2,750,100
REGENXBIO
5/20/2015
$70,500,000
Nabriva Therapeutics
4/13/2015
$120,000,000
Semnur Pharmaceuticals
3/31/2015
$10,000,000
Aclaris Therapeutics
10/2/2014
$21,000,000
Coherus BioSciences
5/19/2014
$55,000,000
ProNAi Therapeutics
4/22/2014
$59,500,000
Nora Therapeutics
4/17/2014
$18,000,000
Ocera Therapeutics
7/17/2013
$20,000,000
Rempex Pharmaceuticals
3/31/2013
$20,000,000
TRIA Beauty
12/31/2012
$7,501,200
Aclaris Therapeutics
10/25/2012
$21,000,000
Ceptaris Therapeutics
6/5/2012
$10,000,000
SentreHEART
6/4/2012
$26,000,000
AirXpanders
1/25/2012
$10,000,000
TRIA Beauty
12/31/2011
$20,000,000
Medley Health
11/16/2011
$20,000,000
Rempex Pharmaceuticals
11/9/2011
$67,500,000
Ceptaris Therapeutics
8/11/2011
$14,400,000
Revance Therapeutics
6/10/2011
$45,000,000
TRIA Beauty
4/20/2011
$21,000,000
Essentialis
10/11/2010
Unknown
Health360
9/30/2010
$7,500,000
Essentialis
9/30/2010
$321,000
Eiger BioPharmaceuticals
9/30/2010
$1,200,000
TRIA Beauty
9/13/2010
$15,600,000
Nora Therapeutics
6/30/2010
$1,932,000
Revance Therapeutics
6/30/2010
$7,815,000
Vicept Therapeutics
6/30/2010
$10,000,000
Synapse Biomedical
3/31/2010
$433,000
NeoMend
1/27/2010
$30,000,000
Nora Therapeutics
12/31/2009
$128,000
Vicept Therapeutics
9/30/2009
$6,000,000
Ceptaris Therapeutics
9/30/2009
$3,140,000
Nuveta
9/16/2009
$800,000
Essentialis
6/30/2009
Unknown
Sagent Pharmaceuticals
5/22/2009
$30,000,000
InteKrin Therapeutics
3/31/2009
$927,000
TRF Pharma
3/31/2009
$6,000,000
Eiger BioPharmaceuticals
2/24/2009
$7,100,000
ViOptix
12/31/2008
$3,000,000
Copernicus Therapeutics
9/30/2008
$999,900
APT Pharmaceuticals
9/30/2008
$32,000,000
Sagent Pharmaceuticals
9/4/2008
$30,000,000
InteKrin Therapeutics
8/4/2008
$18,250,000
Capnia
4/24/2008
$19,200,000
Essentialis
12/31/2007
$8,000,000
Revance Therapeutics
12/12/2007
$43,200,000
Carbylan Therapeutics
11/26/2007
$20,000,000
Ceptaris Therapeutics
11/26/2007
$14,500,000
APT Pharmaceuticals
10/4/2007
$22,000,000
Pavad Medical
9/30/2007
$15,999,900
Sagent Pharmaceuticals
9/27/2007
$53,000,000
OVATION Pharmaceuticals
8/27/2007
$20,000,000
NeoMend
6/30/2007
$10,025,000
Merz Aesthetics
6/30/2007
$11,898,100
Synapse Biomedical
3/31/2007
$4,000,000
NextWave Pharmaceuticals
2/14/2007
$40,000,000
InteKrin Therapeutics
1/11/2007
$23,000,000
Capnia
12/31/2006
$2,000,000
Essentialis
12/31/2006
$966,000
Biodel
8/2/2006
$21,000,000
OVATION Pharmaceuticals
7/24/2006
$60,000,000
Merz Aesthetics
6/30/2006
$11,986,000
Naryx Pharma
5/22/2006
$8,000,000
APT Pharmaceuticals
5/21/2006
$9,000,000
Essentialis
3/31/2006
$620,000
Avera Pharmaceuticals
3/31/2006
$17,999,700
Copernicus Therapeutics
6/30/2005
$825,000
Bayer AG
6/7/2005
$14,350,000
Hamilton Pharmaceuticals
4/22/2005
$11,000,000
Avera Pharmaceuticals
3/31/2005
$18,000,200
OVATION Pharmaceuticals
12/6/2004
$37,000,000

 

Investor Contacts

Title
Name
Email & Social
Managing Director
Gaurav Aggarwal
  Gaurav Aggarwal LinkedIn Profile  Gaurav Aggarwal Twitter Account  Gaurav Aggarwal News  Gaurav Aggarwal on Facebook
Managing Partner
Albert Cha
  Albert Cha LinkedIn Profile  Albert Cha Twitter Account  Albert Cha News  Albert Cha on Facebook
Managing Director
Michael Chang
  Michael Chang LinkedIn Profile  Michael Chang Twitter Account  Michael Chang News  Michael Chang on Facebook
Principal
Dan Dong
  Dan Dong LinkedIn Profile  Dan Dong Twitter Account  Dan Dong News  Dan Dong on Facebook
Managing Partner
Edgar Engleman
  Edgar Engleman LinkedIn Profile  Edgar Engleman Twitter Account  Edgar Engleman News  Edgar Engleman on Facebook
Managing Partner
Shan Fu
  Shan Fu LinkedIn Profile  Shan Fu Twitter Account  Shan Fu News  Shan Fu on Facebook
Managing Partner
Frank Kung
  Frank Kung LinkedIn Profile  Frank Kung Twitter Account  Frank Kung News  Frank Kung on Facebook
Managing Director
Hwachie Lee
  Hwachie Lee LinkedIn Profile  Hwachie Lee Twitter Account  Hwachie Lee News  Hwachie Lee on Facebook
Managing Director
Jack Nielsen
  Jack Nielsen LinkedIn Profile  Jack Nielsen Twitter Account  Jack Nielsen News  Jack Nielsen on Facebook
Managing Director
Mahendra Shah
  Mahendra Shah LinkedIn Profile  Mahendra Shah Twitter Account  Mahendra Shah News  Mahendra Shah on Facebook
Managing Director
Joseph Siletto
  Joseph Siletto LinkedIn Profile  Joseph Siletto Twitter Account  Joseph Siletto News  Joseph Siletto on Facebook
Managing Director
Lawrence Wang
  Lawrence Wang LinkedIn Profile  Lawrence Wang Twitter Account  Lawrence Wang News  Lawrence Wang on Facebook
Managing Partner
Chen Yu
  Chen Yu LinkedIn Profile  Chen Yu Twitter Account  Chen Yu News  Chen Yu on Facebook
Principal
Qi Zhu
  Qi Zhu LinkedIn Profile  Qi Zhu Twitter Account  Qi Zhu News  Qi Zhu on Facebook

 

Funds

Our database includes the following fund closing(s) for Vivo Capital. If we are missing funds, please contact us.

Fund Description
Vintage Date
Fund Amount
Vivo Capital Fund IX
12/7/2018
$863,978,261
Opportunity Fund
9/12/2018
$635,000,000
Vivo PANDA Fund
6/13/2016
$100,000,000
Vivo Capital Fund VIII
12/18/2014
$600,700,000
Vivo Ventures Fund VII
1/3/2012
$375,000,000
Vivo Ventures Fund VI
5/7/2007
$275,000,000

 

Portfolio Companies

Vivo Capital has invested in the companies below, according to our database records. If we are missing a portfolio company, please let us know.

Tech Company
Aadi Bioscience
Aclaris Therapeutics
ADARx Pharmaceuticals
Aerobiotix
AirXpanders
Apellis Pharmaceuticals
APT Pharmaceuticals
Attralus
Avera Pharmaceuticals
Avistone Pharmaceuticals
Bayer AG
Biodel
Biohaven Pharmaceuticals
BlossomHill Therapeutics
Bolt Biotherapeutics
Capnia
Carbylan Therapeutics
Ceptaris Therapeutics
Cerebral Therapeutics
Clasp Therapeutics
Coherus BioSciences
COMPASS Pathways
Copernicus Therapeutics
Crinetics Pharmaceuticals
Delcath Systems
Design Therapeutics
Eiger BioPharmaceuticals
Elevation Oncology
EpiBiologics
Essentialis
Fortis Therapeutics
Hamilton Pharmaceuticals
Harmony Biosciences
Health360
Homology Medicines
IGM Biosciences
Immune-Onc Therapeutics
Impel NeuroPharma
InBrace
Inspirna
InteKrin Therapeutics
Kala Pharmaceuticals
Kira Pharmaceuticals
Klavi
MacuLogix
Medeor Therapeutics
Medley Health
Menlo Therapeutics
Merz Aesthetics
Metacrine
Minerva Surgical
Nabriva Therapeutics
Naryx Pharma
Neocis
NeoMend
Neurogastrx
Nexcida Therapeutics
NextWave Pharmaceuticals
Nora Therapeutics
Nuveta
Ocelot Bio
Ocera Therapeutics
Olema Oncology
Ossium Health
Outpost Medicine
OVATION Pharmaceuticals
Passage Bio
PatientPop
Pavad Medical
Platelet Biogenesis
Poseida Therapeutics
Precision BioSciences
ProNAi Therapeutics
Pulmocide
RayzeBio
REGENXBIO
Rempex Pharmaceuticals
Revance Therapeutics
Revolution Medicines
Ronovo Surgical
Sagent Pharmaceuticals
Scientia Vascular
Semnur Pharmaceuticals
SentreHEART
Sera Prognostics
Swift Health Systems
Synapse Biomedical
Tarsus Pharmaceuticals
Tebra
Terns Pharmaceuticals
Tranquis Therapeutics
TRF Pharma
TRIA Beauty
Tricida
Ventyx Biosciences
Vicept Therapeutics
ViOptix
Zenas BioPharma

 

 

 

 

Browse more venture capital investors:

Vivid Ventures | Vivo Ventures

 

Share this article

 

About Our VC & M&A Database

Our data comes from VentureDeal.com, a leading provider of venture capital transaction data.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.